|
To: [HCP email]
From: Neurology Live <news@neurologylive.com>
Subject: Discover the History of mAbs for Preventive Treatment of Migraine
No Images? Click here
|
|
|
Discover the History of Monoclonal
Antibodies and the Pathophysiology
of CGRP in Migraine
This iPub® is sponsored by Lundbeck and is not
approved for Continuing Medical Education.
|
|
|
Join expert faculty in this educational iPub® to learn more
about migraine pathophysiology and a therapeutic option for
migraine prevention.
|
|
|
|
|
Jessica Ailani, MD, FAHS, FAAN
Professor of Clinical Neurology
Director, Georgetown Headache Center
MedStar Georgetown University Hospital
Washington, DC
|
|
|
|
Andrew Charles, MD
Professor of Neurology
Meyer and Renee Luskin Chair in Migraine and
Headache Studies
Director, Goldberg Migraine Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
|
|
|
|
|
|
In this iPub®, Drs. Jessica Ailani and Andrew Charles will:
|
|
|
|
|
Provide an overview of migraine pathophysiology,
the history and design considerations of
therapeutic monoclonal antibodies, and the basis
for targeting calcitonin gene-related peptide
(CGRP) for the treatment of migraine
|
|
|
|
|
|
|
Present the results from recent clinical trials
demonstrating the efficacy and safety of a
monoclonal antibody in the preventive treatment
of migraine
|
|
|
|
|
|
|
Review current recommendations for migraine prevention and examine characteristics for patient selection
|
|
|
|
|
|
|
|
|
|
|
© 2020 Lundbeck. All rights reserved.
MIG-D-100118
|
|
|
|
|
|
|
|
Neurology Live® – an MJH Life Sciences™ brand
Copyright 2020 © Intellisphere, LLC
2 Clarke Dr | Suite 100 | Cranbury, NJ | 08512
Preferences | Unsubscribe
|
Tweet
|
|
|
|
|
